Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Sino Biopharmaceutical Secures Exclusive Global Rights to Yikexin TRACE Treatment Series Through CTTQ Partnership with Beijing CIST

Fineline Cube Jul 9, 2026
Company Deals

Xenovector and Jilin University Launch Strategic Partnership to Advance Gene-Edited Pig Organ Transplantation from Breakthrough to Affordable Healthcare

Fineline Cube Jul 9, 2026
Company Deals

Zhejiang Hisun Pharmaceutical and Tigermed Forge Strategic Alliance to Create End-to-End Innovative Drug Development Pipeline

Fineline Cube Jul 9, 2026
Company Deals

Transcenta Returns Select Lilly Assets in Portfolio Restructuring, Retains Blosozumab Rights

Fineline Cube Jul 8, 2026
Company Deals Digital

Hanx Biopharmaceuticals Partners with HUST-CityU Macau Institute to Establish AI-Driven Drug Discovery Joint Laboratory

Fineline Cube Jul 8, 2026
Policy / Regulatory

China’s National Health Commission Unveils 2026 Essential Medicines List, Adding 116 New Drugs with Full Insurance Coverage

Fineline Cube Jul 9, 2026
Company Drug

Astellas Pharma Submits BLA to China NMPA for PADCEV-Keytruda Combination in Muscle-Invasive Bladder Cancer, Showing 60% Reduction in Recurrence Risk for Cisplatin-Ineligible Patients

Fineline Cube Jul 9, 2026
Company Drug

Jiangsu Aidea Pharmaceutical Receives NMPA Clinical Trial Approval for ADC119, China’s First Domestic Complete HIV Regimen Combining Novel NNRTI with Established NRTIs

Fineline Cube Jul 9, 2026
Company

GSK’s CCO Calls China a Hotbed for Innovative Molecules and Licensing Deals

Fineline Cube Dec 19, 2023

In an interview with the Financial Times, Luke Miels, Chief Commercial Officer of UK-based GlaxoSmithKline...

Company Deals

Biocytogen and Ona Therapeutics Forge Antibody Evaluation and Licensing Agreement

Fineline Cube Dec 19, 2023

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315), based in China, has entered into an antibody...

Company Deals

WuXi Biologics Partners with Visen Pharmaceuticals for Lonapegsomatropin Manufacturing

Fineline Cube Dec 19, 2023

China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has entered into...

Company Drug

Keytruda Gains 12th Indication Approval in China for HER2-Negative Gastric Cancer

Fineline Cube Dec 19, 2023

US pharmaceutical giant Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced that its immunotherapy...

Company Drug

Sirnaomics Ltd Granted FDA Approval for Phase I RSV mRNA Vaccine Study

Fineline Cube Dec 19, 2023

Sirnaomics Ltd (HKG: 2257) has received approval from the US Food and Drug Administration (FDA)...

Company Drug

Roche Receives NMPA Approval for Ophthalmology BsAb Vabysmo (Farcimab) for Diabetic Macular Edema

Fineline Cube Dec 19, 2023

Swiss pharmaceutical giant Roche (SWX: ROG) has announced that it has obtained marketing approval from...

Company Drug

Huadong Medicine Gets NMPA Green Light for Clinical Study of Ryzodeg Biosimilar

Fineline Cube Dec 19, 2023

China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that it has received approval from...

Company Deals

Fosun Pharmaceutical Secures GHIT Fund Investment for Malaria Drug Trial

Fineline Cube Dec 18, 2023

Shanghai Fosun Pharmaceutical Co., Ltd (SHA: 600196, HKG: 2196) has received financial backing of JPY...

Company Drug

FDA Approves Pfizer-Astellas-MSD Combo Therapy for Advanced Urothelial Cancer

Fineline Cube Dec 18, 2023

Pfizer (NYSE: PFE), Astellas (TYO: 4503), and Merck, Sharp & Dohme (MSD; NYSE: MRK) have...

Medical Device Policy / Regulatory

China Releases Emergency Use Rules for Medical Devices Amid Public Health Emergencies

Fineline Cube Dec 18, 2023

The National Medical Products Administration (NMPA), National Health Commission (NHC), and Chinese Center for Disease...

Company Deals

Novo Nordisk Acquires Alkermes’ Irish Production Site for $92.5 Million to Boost GLP-1 Output

Fineline Cube Dec 18, 2023

Novo Nordisk (CPH: NOVO-B), a Danish pharmaceutical giant, has reached an agreement to acquire a...

Company Deals

Reetoo Biotechnology Boosts AI in Medical Diagnostics with $14 Million Funding Round

Fineline Cube Dec 18, 2023

Shenzhen Reetoo Biotechnology Co., Ltd, a Chinese firm at the forefront of integrating artificial intelligence...

Company Drug

Bio-Thera Solutions Gets NMPA Green Light for PD-1 Inhibitor BAT1308 in Endometrial Cancer

Fineline Cube Dec 18, 2023

Bio-Thera Solutions Ltd (SHA: 688177), a biopharmaceutical company based in China, has announced that it...

Company Deals

Mingyi Zhizao Secures $14 Million to Scale Gene Sequencing Platform and Production

Fineline Cube Dec 18, 2023

Shenzhen Mingyi Zhizao Technology Co., Ltd, a Chinese company specializing in the gene sequencing industry,...

Company

Shanghai Pharmaceuticals Hit with Anti-Monopoly Fine by Shanghai Market Supervision Bureau

Fineline Cube Dec 18, 2023

Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607), a leading pharmaceutical distribution company based in China,...

Company Deals

Youcare Pharmaceutical Partners with Sinopharm Heilongjiang to Broaden Market Presence

Fineline Cube Dec 18, 2023

Youcare Pharmaceutical Group (SHA: 688658), a China-based pharmaceutical company, has entered into a partnership with...

Company Drug

Sanofi’s Rezurock Secures Marketing Approval in China for Chronic Graft-vs-Host Disease

Fineline Cube Dec 18, 2023

French pharmaceutical giant Sanofi (NASDAQ: SNY) has announced that its drug Rezurock (belumosudil), the world’s...

Company Drug

InnoCare’s TYK2 Inhibitor ICP-332 Shows Positive Results in Atopic Dermatitis Phase II Study

Fineline Cube Dec 18, 2023

Beijing InnoCare Pharma Tech Co., (HKG: 9969), a Chinese biotechnology company specializing in oncology and...

Company Drug

MSD’s Welireg Gains FDA Approval for Advanced Renal Cell Carcinoma

Fineline Cube Dec 15, 2023

The US Food and Drug Administration (FDA) has granted an indication extension approval for Merck,...

Company Deals

Bayer Partners with ClearNote Health to Explore Prostate Cancer Treatment Response

Fineline Cube Dec 15, 2023

German multinational pharmaceutical company Bayer (ETR: BAYN) has partnered with U.S. diagnostics firm ClearNote Health...

Posts pagination

1 … 455 456 457 … 693

Recent updates

  • Astellas Pharma Submits BLA to China NMPA for PADCEV-Keytruda Combination in Muscle-Invasive Bladder Cancer, Showing 60% Reduction in Recurrence Risk for Cisplatin-Ineligible Patients
  • Jiangsu Aidea Pharmaceutical Receives NMPA Clinical Trial Approval for ADC119, China’s First Domestic Complete HIV Regimen Combining Novel NNRTI with Established NRTIs
  • Shenyang Xingqi Pharmaceutical Reports Positive Phase 2 Results for SQ-22031 Eye Drops in Neurotrophic Keratitis, Advances to Pivotal Phase 3 Trial
  • Sino Biopharmaceutical Secures Exclusive Global Rights to Yikexin TRACE Treatment Series Through CTTQ Partnership with Beijing CIST
  • Changchun High & New Technology’s Subsidiary GenSci Secures NMPA IND Acceptance for GenSci148, First-in-Class VEGF Multi-Blocker for Retinal Vascular Diseases
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Astellas Pharma Submits BLA to China NMPA for PADCEV-Keytruda Combination in Muscle-Invasive Bladder Cancer, Showing 60% Reduction in Recurrence Risk for Cisplatin-Ineligible Patients

Company Drug

Jiangsu Aidea Pharmaceutical Receives NMPA Clinical Trial Approval for ADC119, China’s First Domestic Complete HIV Regimen Combining Novel NNRTI with Established NRTIs

Company Drug

Shenyang Xingqi Pharmaceutical Reports Positive Phase 2 Results for SQ-22031 Eye Drops in Neurotrophic Keratitis, Advances to Pivotal Phase 3 Trial

Company Deals

Sino Biopharmaceutical Secures Exclusive Global Rights to Yikexin TRACE Treatment Series Through CTTQ Partnership with Beijing CIST

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.